Variants of estrogen-related genes and breast cancer risk in European and African American women

Endocrine-Related Cancer

Volumn 21, Issue 6, 2014, Pages 853-864

  Quan, Lei ^a,b   Hong, Chi Chen ^a   Zirpoli, Gary ^a   Roberts, Michelle R ^a   Khoury, Thaer ^a   Sucheston Campbell, Lara E ^a   Bovbjerg, Dana H ^b   Jandorf, Lina ^c   Pawlish, Karen ^d   Ciupak, Gregory ^a   Davis, Warren ^a   Bandera, Elisa V ^e   Ambrosone, Christine B ^a   Yao, Song ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

African American; Breast cancer; Disparity; ESR1; Estrogen metabolism; Estrogen receptor; Estrogen response; Estrogen synthesis

Indexed keywords

CYTOCHROME P450 1A2; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AFRICAN AMERICAN; BREAST TUMOR; CANCER STAGING; CAUCASIAN; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A2; ESTROGENS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84919647838     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0250     Document Type: Article

References (67)

1. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP & Sherman ME 2004 Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiology, Biomarkers and Prevention 13 1558-1568.
2. Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, Pawlish K, Godbold J, Furberg H, Fatone A et al. 2009 Conducting molecular epidemiological research in the age of HIPAA: a multiinstitutional case-control study of breast cancer in African-American and European-American women. Journal of Oncology 2009 871250. (doi:10.1155/2009/871250)
3. Ambrosone CB, Zirpoli G, RuszczykM, Shankar J, Hong CC, McIlwain D, RobertsM,YaoS,McCannSE,CiupakGet al.2014a Parity and breast feeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in theWomen's Circle of Health Study. Cancer Causes & Control 25 259-265. (doi:10.1007/s10552-013-0323-9)
4. Ambrosone CB, Zirpoli GR, Bovbjerg DH, Shankar J, Hong CC, McCann SE, Ruszczyk M, Khoury T, Yao S, Ciupak GL et al. 2014b Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African-American and European- American women. Cancer Epidemiology, Biomarkers and Prevention 23 1115-1120. (doi:10.1158/1055-9965.EPI-14-0110)
5. Amend K, Hicks D & Ambrosone CB 2006 Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Research 66 8327-8330. (doi:10.1158/0008-5472.CAN-06-1927)
6. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE & Lindeman GJ 2006 Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute 98 1011-1014. (doi:10.1093/jnci/djj267)
7. Bandera EV, Chandran U, Zirpoli G,McCann SE, Ciupak G & Ambrosone CB 2013 Rethinking sources of representative controls for the conduct of case-control studies in minority populations. BMC Medical Research Methodology 13 71. (doi:10.1186/1471-2288-13-71)
8. Bergman-Jungestrom M, Gentile M, Lundin AC & Wingren S 1999 Association between CYP17 gene polymorphism and risk of breast cancer in young women. International Journal of Cancer 84 350-353. (doi:10.1002/(SICI)1097-0215(19990820)84:4!350::AID-IJC3O3.0.CO;2-L)
9. Brett KM &Madans JH 1997 Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. American Journal of Epidemiology 145 536-545. (doi:10.1093/oxfordjournals.aje.a009142)
10. CampaD,Kaaks R, LeMarchandL,HaimanCA, Travis RC, BergCD, Buring JE, Chanock SJ, Diver WR, Dostal L et al. 2011 Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. Journal of the National Cancer Institute 103 1252-1263. (doi:10.1093/jnci/djr265)
11. Chen F, Chen GK, Millikan RC, John EM, Ambrosone CB, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Deming SL et al. 2011 Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Human Molecular Genetics 20 4491-4503. (doi:10.1093/hmg/ddr367)
12. ChlebowskiRT,ChenZ,AndersonGL, RohanT,Aragaki A, Lane D,DolanNC, Paskett ED, McTiernan A, Hubbell FA et al. 2005 Ethnicity and breast cancer: factors influencing differences in incidence and outcome. Journal of the National Cancer Institute 97 439-448. (doi:10.1093/jnci/dji064)
13. Dunning AM, Healey CS, Baynes C,Maia AT, Scollen S, Vega A, Rodriguez R, Barbosa-Morais NL, Ponder BA, Search et al. 2009 Association of ESR1 gene tagging SNPs with breast cancer risk. Human Molecular Genetics 18 1131-1139. (doi:10.1093/hmg/ddn429)
14. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK & Henderson BE 1997 A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Research 57 1063-1065.
15. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ & Henderson BE 1998 Cytochrome P450c17a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Research 58 585-587.
16. Fregene A & Newman LA 2005 Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer 103 1540-1550. (doi:10.1002/cncr.20978)
17. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, Veenstra TD et al. 2012 Estrogen metabolism and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 104 326-339. (doi:10.1093/jnci/djr531)
18. Fuqua SA & Wolf DM 1995 Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Research and Treatment 35 233-241. (doi:10.1007/BF00665974)
19. Germain D 2011 Estrogen carcinogenesis in breast cancer. Endocrinology and Metabolism Clinics of North America 40 473-484, vii. (doi:10.1016/j.ecl.2011.05.009)
20. Gordon NH 1995 Association of education and income with estrogen receptor status in primary breast cancer. American Journal of Epidemiology 142 796-803.
21. Haiman CA & Stram DO 2010 Exploring genetic susceptibility to cancer in diverse populations. Current Opinion in Genetics and Development 20 330-335. (doi:10.1016/j.gde.2010.02.007)
22. Hartge P 2006 Participation in population studies. Epidemiology 17 252-254. (doi:10.1097/01.ede.0000209441.24307.92)
23. Hinch AG, Tandon A, Patterson N, Song Y, Rohland N, Palmer CD, Chen GK, Wang K, Buxbaum SG, Akylbekova EL et al. 2011 The landscape of recombination in African Americans. Nature 476 170-175. (doi:10.1038/nature10336)
24. Hong CC, Tang BK, Hammond GL, Tritchler D, Yaffe M & Boyd NF 2004 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Research 6 R352-R365. (doi:10.1186/bcr798)
25. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O et al. 2009 Population differences in breast cancer: survey in indigenous African women reveals overrepresentation of triple-negative breast cancer. Journal of Clinical Oncology 27 4515-4521. (doi:10.1200/JCO.2008.19.6873)
26. Hutter CM, Young AM, Ochs-Balcom HM, Carty CL, Wang T, Chen CT, Rohan TE, Kooperberg C & Peters U 2011 Replication of breast cancer GWAS susceptibility loci in the Women's Health Initiative African American SHARe Study. Cancer Epidemiology, Biomarkers & Prevention 20 1950-1959. (doi:10.1158/1055-9965.EPI-11-0524)
27. Hwang ES, Chew T, Shiboski S, Farren G, Benz CC &Wrensch M 2005 Risk factors for estrogen receptor-positive breast cancer. Archives of Surgery 140 58-62. (doi:10.1001/archsurg.140.1.58)
28. Kato I, Cichon M, Yee CL, Land S & Korczak JF 2009 African Americanpreponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiology 33 24-30. (doi:10.1016/j.canep. 2009.04.009)
29. Key T, Appleby P, Barnes I, Reeves G & Endogenous Harmones and Breast Cancer Collaborative Group 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616. (doi:10.1093/jnci/94.8.606)
30. Krieger N, Chen JT, Ware JH & Kaddour A 2008 Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions. Cancer Causes & Control 19 1305-1318. (doi:10.1007/s10552-008-9202-1)
31. Li N, Dong J, Hu Z, Shen H & Dai M 2010 Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment 121 177-184. (doi:10.1007/s10549-009-0532-9)
32. Liang J & Shang Y 2013 Estrogen and cancer. Annual Review of Physiology 75 225-240. (doi:10.1146/annurev-physiol-030212-183708)
33. Liehr JG 1997 Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. European Journal of Cancer Prevention 6 3-10. (doi:10.1097/00008469-199702000-00002)
34. Long J, Zhang B, Signorello LB, Cai Q, Deming-Halverson S, Shrubsole MJ, Sanderson M, Dennis J, Michailiou K, Easton DF et al. 2013 Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. PLoS ONE 8 e58350. (doi:10.1371/journal.pone.0058350)
35. Loud JT, Gierach GL, Veenstra TD, Falk RT, Nichols K, Guttmann A, Xu X, GreeneMH& GailMH2014 Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Research and Treatment 143 517-529. (doi:10.1007/s10549-013-2821-6)
36. Michailidou K, Hall P, Gonzalez-Neira A, GhoussainiM, Dennis J,Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK et al. 2013 Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics 45 353-361, 361e351-361e352. (doi:10.1038/ng.2563)
37. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT et al. 2008 Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment 109 123-139. (doi:10.1007/s10549-007-9632-6)
38. Miyoshi Y & Noguchi S 2003 Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomedicine and Pharmacotherapy 57 471-481. (doi:10.1016/j.biopha.2003.09.008)
39. Narum SR 2006 Beyond Bonferroni: less conservative analyses for conservation genetics. Conservation Genetics 7 783-787. (doi:10.1007/s10592-005-9056-y)
40. O'BrienKM, Cole SR, PooleC, Bensen JT, Herring AH, Engel LS&MillikanRC 2014 Replication of breast cancer susceptibility loci in whites and African Americans using a Bayesian approach. American Journal of Epidemiology 179 382-394. (doi:10.1093/aje/kwt258)
41. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL & Rosenberg L 2011 Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiology, Biomarkers & Prevention 20 1883-1891. (doi:10.1158/1055-9965.EPI-11-0465)
42. Palmer JR, Ruiz-Narvaez EA, Rotimi CN, Cupples LA, Cozier YC, Adams- Campbell LL & Rosenberg L 2013 Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiology, Biomarkers & Prevention 22 127-134. (doi:10.1158/1055-9965.EPI-12-0769)
43. Pike MC, Spicer DV, Dahmoush L & PressMF 1993 Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiologic Reviews 15 17-30.
44. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL & Hankinson SE 2005 Racial differences in premenopausal endogenous hormones. Cancer Epidemiology, Biomarkers & Prevention 14 2147-2153. (doi:10.1158/1055-9965.EPI-04-0944)
45. Pritchard JK, Stephens M, Rosenberg NA & Donnelly P 2000 Association mapping in structured populations. American Journal of Human Genetics 67 170-181. (doi:10.1086/302959)
46. Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW et al. 2014 Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 35 1012-1019. (doi:10.1093/carcin/bgt404)
47. Quan L,Gong Z, Yao S, Bandera EV, Zirpoli G,HwangH,Roberts M, Ciupak G, DavisW, Sucheston L et al. 2014 Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry. International Journal of Cancer 134 1408-1421. (doi:10.1002/ijc.28458)
48. Raftogianis R, Creveling C, Weinshilboum R & Weisz J 2000 Estrogen metabolism by conjugation. Journal of the National Cancer Institute. Monographs 27 113-124. (doi:10.1093/oxfordjournals.jncimonographs.a024234)
49. Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A et al. 2007 Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiology, Biomarkers & Prevention 16 444-450. (doi:10.1158/1055-9965.EPI-06-0800)
50. Reding KW, Chen C, Lowe K, Doody DR, Carlson CS, Chen CT, Houck J, Weiss LK,Marchbanks PA, Bernstein L et al. 2012 Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes & Control 23 671-681. (doi:10.1007/s10552-012-9925-x)
51. Ruiz-Narvaez EA, Rosenberg L, Wise LA, Reich D & Palmer JR 2011 Validation of a small set of ancestral informative markers for control of population admixture in African Americans. American Journal of Epidemiology 173 587-592. (doi:10.1093/aje/kwq401)
52. Santen RJ & Allred DC 2007 The estrogen paradox. Nature Clinical Practice. Endocrinology & Metabolism 3 496-497. (doi:10.1038/ncpendmet0535)
53. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV & Gottesman MM 2007 Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Research 67 9609-9612. (doi:10.1158/0008-5472.CAN-07-2377)
54. Setiawan VW, Cheng I, Stram DO, Giorgi E, Pike MC, Van Den Berg D, Pooler L, Burtt NP, Le Marchand L, Altshuler D et al. 2006 A systematic assessment of common genetic variation in CYP11A and risk of breast cancer. Cancer Research 66 12019-12025. (doi:10.1158/0008-5472.CAN-06-1101)
55. Sims AH, Howell A, Howell SJ & Clarke RB 2007 Origins of breast cancer subtypes and therapeutic implications. Nature Clinical Practice. Oncology 4 516-525. (doi:10.1038/ncponc0908)
56. Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF et al. 2000 CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. Journal of the National Cancer Institute 92 1674-1681. (doi:10.1093/jnci/92.20.1674)
57. Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD et al. 2010 Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genetics 6 e1001029. (doi:10.1371/journal. pgen.1001029)
58. Taioli E, Trachman J, Chen X, Toniolo P & Garte SJ 1995 A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Research 55 3757-3758.
59. Tang L, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Kristal AR, Platz EA, Neuhouser ML, Stanczyk FZ et al. 2011 Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 32 1500-1506. (doi:10.1093/carcin/bgr139)
60. Thompson PA & Ambrosone C 2000 Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. Journal of the National Cancer Institute. Monographs 27 125-134. (doi:10.1093/oxfordjournals.jncimonographs.a024235)
61. Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Perrier ND, Freimanis RI, Allen GO, Rubin P, Sherrill GB, Shaw CS et al. 2008 Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncology Reports 19 1311-1321. (doi:10.3892/or.19.5.1311)
62. Yager JD & Davidson NE 2006 Estrogen carcinogenesis in breast cancer. New England Journal of Medicine 354 270-282. (doi:10.1056/NEJMra050776)
63. Yao S, Zirpoli G, Bovbjerg DH, Jandorf L, Hong CC, Zhao H, Sucheston LE, Tang L, Roberts M, Ciupak G et al. 2012 Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Research 14 R58. (doi:10.1186/bcr3162)
64. Yu W, Gwinn M, Clyne M, Yesupriya A & Khoury MJ 2008 A navigator for human genome epidemiology. Nature Genetics 40 124-125. (doi:10.1038/ng0208-124)
65. Zheng W, Cai Q, Signorello LB, Long J, Hargreaves MK, Deming SL, Li G, Li C, Cui Y & Blot WJ 2009a Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiology, Biomarkers & Prevention 18 2761-2764. (doi:10.1158/1055-9965.EPI-09-0624)
66. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL et al. 2009b Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nature Genetics 41 324-328. (doi:10.1038/ng.318)
67. Zhu BT, Han GZ, Shim JY, Wen Y & Jiang XR 2006 Quantitative structure- activity relationship of various endogenous estrogen metabolites for human estrogen receptor a and b subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 147 4132-4150. (doi:10.1210/en.2006-0113)